Journal article
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
SI Richardson, AW Chung, H Natarajan, B Mabvakure, NN Mkhize, N Garrett, S Abdool Karim, PL Moore, ME Ackerman, G Alter, L Morris
Plos Pathogens | PUBLIC LIBRARY SCIENCE | Published : 2018
Open access
Abstract
While the induction of broadly neutralizing antibodies (bNAbs) is a major goal of HIV vaccination strategies, there is mounting evidence to suggest that antibodies with Fc effector function also contribute to protection against HIV infection. Here we investigated Fc effector functionality of HIV-specific IgG plasma antibodies over 3 years of infection in 23 individuals, 13 of whom developed bNAbs. Antibody-dependent cellular phagocytosis (ADCP), complement deposition (ADCD), cellular cytotoxicity (ADCC) and cellular trogocytosis (ADCT) were detected in almost all individuals with levels of activity increasing over time. At 6 months post-infection, individuals with bNAbs had significantly hig..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
SIR is funded by the National Research foundation (http://www.nrf.ac.za/), the Poliomyelitis Foundation (http://www.prf.ac.za/), the University of the Witwatersrand and was supported by two Collaboration for AIDS Vaccine Scientific Exchange Travel Fellowships from the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org/). This study was funded by the South African Medical Research Council Flagship Program (http://www.mrc.ac.za/) and the National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) R01 grant number: R01AI104387. CAPRISA is funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes for Health (NIH), and U.S. Department of Health and Human Services (grant: AI51794). P.L.M. is supported by the South African Research Chairs Initiative of the Department of Science and Technology and the National Research Foundation (Grant No 98341). M.E.A. is supported by Bill and Melinda Gates Foundation OPP1114729, OPP1146996, National Institutes of Health 1P01AI120756 (NIAID), 1R0AI131975 (NIAID and NIGMS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript.